A comparison of calcium-based phosphorus binders for patients with chronic kidney disease

Dialysis and Transplantation

Volumn 35, Issue 5, 2006, Pages 284-293,-336

  Emmett, Michael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM LACTATE; CINACALCET; CITRATE CALCIUM; GLUCONATE CALCIUM; SEVELAMER;

CALCIUM ABSORPTION; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; DRUG SOLUBILITY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IN VITRO STUDY; KIDNEY FAILURE; PATHOGENESIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW;

EID: 54549102297     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20018     Document Type: Review

References (57)

1. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Edited by NIo Health. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
2. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169.
3. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606-1615.
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
5. Levin NW, Hoenich NA: Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens. 2001;10:563-568.
6. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
7. Marriott WM, Howland J. Phosphate retention as a factor in the production of acidosis in nephritis. Arch Intern Med. 1916;708.
8. Bricker NS, Slatopolsky E, Reiss E, Avioli LV:.Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med. 1969;123:543-553.
9. Bricker NS. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis." N Engl J Med. 1972;286:1093-1099.
10. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35:1226-1237.
11. K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
12. Davis GR, Zerwekh JE, Parker TF, Krejs GJ, Pak CY, Fordtran JS. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency. Gastroenterology. 1983;85:908-916.
13. Schiavi SC, Kumar R: The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004;65:1-14.
14. Slatopolsky E, Robson AM, Elkan I, Bricker NS. Control of phosphate excretion in uremic man. J Clin Invest. 1968;47:1865-1874.
15. Rufino M, de Bonis E, Martin M, et al. Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant. 1998;13 Suppl 3:65-67.
16. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis. 1997;29:641-649.
17. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, Bourdeau JE. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis. 1991;18:217-224.
18. Zucchelli P, Santoro A. Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs. 1987;10:173-178.
19. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
20. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53:1399-1404.
21. Freeman S, Freeman WMC: Phosphorous retention in children with chronic renal insufficiency. Am J Dis Child. 1941;61:981-1002.
22. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294:184-188.
23. Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med. 1984;310:1079-1084.
24. Clarkson EM, McDonald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966;30:425-438.
25. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986;315:157-161.
26. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83:66-73.
27. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989;36:690-695.
28. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis. 1991;17:544-550.
29. Ben Hamida F, el Esper I, Compagnon M, Moriniere P, Fournier A. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron. 1993;63:258-262.
30. Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol. 1992;3:96-102.
31. Caravaca F, Santos I, Cubero JJ, et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron. 1992;60:423-427.
32. Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant. 1991;6:170-175.
33. Moriniere P, Djerad M, Boudailliez B, et al. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron. 1992;60:6-11.
34. Gold CH, Morley JE, Viljoen M, Tim LO, de Fomseca M, Kalk WJ. Gastric acid secretion and serum gastrin levels in patients with chronic renal failure on regular hemodialysis. Nephron. 1980;25:92-95.
35. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs. 1998;22:569-573.
36. Tan CC, Harden PN, Rodger RS, et al. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant. 1996;11:851-853.
37. Gonella M, Calabrese G, Vagelli G, Pratesi G, Lamon S, Talarico S. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment. Clin Nephrol. 1985;24:147-150.
38. Sheikh MS, Ramirez A, Emmett M, Santa Ana C, Schiller LR, Fordtran JS. Role of vitamin D-dependent and vitamin D-independent mechanisms in absorption of food calcium. J Clin Invest. 1988;81:126-132.
39. Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis. 1990;16:459-464.
40. Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int. 2002;62:367-374.
41. Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis. 2001;38:S34-S40.
42. Slatopolsky E, Weerts C, Norwood K, et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. 1989;36:897-903.
43. Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int. 1993;43:630-640.
44. Goodman WG. Calcimimetic agents for the treatment of secondary hyperparathyroidism. Semin Nephrol. 2004;24:460-463.
45. Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. Kidney Int. 2004;Suppl:S46-S48.
46. Cushner HM, Copley JB, Lindberg JS, Foulks CJ. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF. Kidney Int. 1988;33:95-99.
47. Dunstan CR, Eade YL, Evans M, Evans RA, Collett PV. The effectiveness of a soluble calcium preparation as a gut phosphate binder. Metabolism. 1988;37:815-819.
48. Zimmermann E, Wassmer S, Steudle V. Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism. Miner Electrolyte Metab. 1996;22:196-199.
49. Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study. Nephrol Dial Transplant. 1999;14:1475-1479.
50. Legendre JY, Cote S, Pradeau D, et al. Efficient phosphate binding using a combination of gluconolactate and carbonate calcium salts. J Clin Pharm Ther. 1994;19:233-238.
51. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. 1990;38:937-941.
52. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27:394-401.
53. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
54. Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant. 1998;13:2037-2040.
55. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003;14:159-168.
56. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
57. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med. 1989;320:1110-1113.